Thelansis’s "Moderate to Severe Dry Eye Disease (DED) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Moderate to Severe Dry Eye Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Moderate to severe dry eye disease is a multifactorial disorder of the ocular surface characterized by loss of tear-film homeostasis, tear instability, inflammation, and, in some patients, epithelial damage. Meibomian gland dysfunction, aqueous deficiency, and neurosensory abnormalities contribute to different disease phenotypes and can produce discomfort, burning, photophobia, and fluctuating vision. Artificial tears remain foundational, but management has expanded substantially beyond lubrication to include anti-inflammatory therapies, tear-evaporation control, and stimulation of endogenous tearing. Established treatments now include cyclosporine, lifitegrast, perfluorohexyloctane, and the cholinergic nasal spray varenicline. The treatment landscape broadened further in 2025 with FDA approval of acoltremon, a TRPM8 agonist that stimulates tear production and improved tear-production endpoints in randomized trials. Next-generation development is increasingly focused on phenotype-specific mechanisms, including kinase inhibition and other approaches targeting ocular-surface inflammation, tear secretion, and glandular dysfunction. OT202, a dual SYK/VEGFR-2 inhibitor, demonstrated activity in a 2026 Phase 2 study and has entered Phase 3 development. For stakeholders, moderate to severe DED represents an increasingly segmented therapeutic market in which the next advances are likely to come from matching mechanism to phenotype and achieving more durable restoration of tear-film and ocular-surface homeostasis.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Moderate to Severe Major Depressive Disorder – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report
Our team will get in touch with you shortly about the Moderate to Severe Major Depressive Disorder – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report.